IRFACILITIES

Liver hemangioma percutaneous ablation Recent research has demonstrated that radiofrequency (RF) ablation therapy is a safe, practicable, and successful treatment for hepatic hemangiomas, even extremely large ones. In the treatment of hepatic hemangiomas, RF ablation provides the following benefits: minimal invasiveness, clear efficacy, high safety, quick recovery, relatively straightforward operation, and broad applicability. To standardise the use of RF ablation for the management of hepatic hemangiomas, a consensus must be reached among Chinese experts with extensive knowledge and experience in the treatment of hepatic hemangiomas using this technique. This consensus must address the selection of patients with appropriate indications for RF ablation treatment, the technical details of the techniques, therapeutic effect evaluations, and management. A Chinese panel of specialists with experience utilising RF ablation to treat hepatic hemangiomas came to a final decision after reviewing the available literature, having a thorough discussion, and approving the document. The most frequent benign tumour of the human liver, hepatic hemangiomas have an incidence of 0.4 percent to 20 percent in the general population and a frequency of 0.4 percent to 7.3 percent when discovered incidentally at autopsy. The majority of accidentally discovered and asymptomatic hepatic hemangiomas don't require treatment. The potential of a life-threatening spontaneous rupture and bleeding is present in peripherally situated hemangiomas as well as big hepatic hemangiomas (5 cm) that induce considerable symptoms. A wide range of medicines have been used to treat hepatic hemangiomas. The most popular treatments in the past have been surgical enucleation and resection. Transcatheter arterial embolization is one of the minimally invasive treatments for hepatic hemangiomas (TAE). In a few rare cases, orthotopic liver transplantation has been done as a therapy option. Due to its distinct advantages over other therapies, such as limited invasiveness, low cost, low incidence of problems, short hospital stay, and increased patient compliance, RF ablation has been employed for treating hepatic hemangiomas more and more in recent years. clinical characteristics and pathology Although up to 40% of patients may have numerous lesions in both hepatic lobes, hepatic hemangiomas typically only have one tumour mass. Cavernous, sclerosing, hemangioendothelial, and capillary hemangiomas are examples of hepatic hemangiomas. It manifests as a veritable chaotic entanglement of distorted blood vessels that are confined to a region as small as a few millilitres and as large as 10 cm, 20 cm, and even 40 cm. It is made up of blood-filled cavities that are fed by the hepatic arterial circulation and have walls lined by a single layer of endothelial cells. Hepatic hemangiomas can be categorised into three sizes based on their diameter: small (5 cm), big (5–9.9 cm), and huge (10 cm). A diameter more than 4 cm is another way that giant hemangiomas are identified in the literature. Diagnosis Hepatic hemangiomas are typically asymptomatic, especially when they are less than 4 cm in size. They are most likely found by accident during imaging tests for other illnesses. The right upper abdomen pain, decreased appetite, premature satiation sensation, nausea, vomiting, and stomach discomfort including a sense of fullness and postprandial bloating are only a few of the non-specific clinical symptoms that some patients may experience (early or late). The most serious consequence is spontaneous or traumatic rupture. This has disastrous consequences if not treated right away, which is why accurate diagnosis and treatment are crucial. Due to their distinctive imaging properties, magnetic resonance imaging (MRI), contrast-enhanced US, and computed tomography (CT) can all be used to specifically detect hepatic hemangiomas. If the results of the ultrasonography are equivocal or if a huge hemangioma needs to be treated, it is advised to use further imaging methods for confirmation, such as contrast-enhanced CT or MRI. On CT or MRI images, the normal hemangioma is shown as a hypointense, well defined lesion; however, after contrast injection, there is increasing homogenous centripetal filling and peripheral nodular enhancement. Hepatic arterial angiography is performed before to TAE to evaluate the tumor's blood supply, size, number, location, and intrahepatic vascular variations. The tumour vasculature are then embolized using an embolization agent mixed with pingyangmycin or bleomycin after the superselective catheterization of the hepatic arteries leading to the tumour body. The blood supply to the hemangioma's body is blocked by the formation of thrombosis, which is caused by the death of endothelial cells lining the blood sinus.